Please use this identifier to cite or link to this item:
|SHARE CORE BASE|
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE|
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
|Authors:||Sousa, José M.; Vergara, Mercedes; Pulido, Federico; Sánchez-Antolín, Gloria; Hijona, Lander; Carnicer, Fernando; Rincón, Diego; Salmerón, Javier; Mateos-Muñoz, Beatriz; Jou, Antoni; Polo-Lorduy, Benjamín; Rubín, Ángel; Escarda, Ana; Aguilar, Patricia; Aldámiz-Echevarría, Teresa; García-Buey, Luisa; Carrión, José A.; Hernández-Guerra, Manuel; Chimeno-Hernández, Sonia; Espinosa, Nuria CSIC ORCID; Morillas, Rosa María; Andrade, Raúl J.; Delgado, Manuel; Gallego, Adolfo; Magaz, Marta; Moreno-Planas, José M.; Estébanez, Ángel; Rico, Mikel; Menéndez, Fernando; Sampedro, Blanca; Morano-Amado, Luis E.; Izquierdo, Sonia; Zozaya, José Manuel; Rodríguez, Manuel; Morán-Sánchez, Senador; Lorente, Sara; Martín-Granizo, Ignacio; von Wichman, Miguel A.; Delgado-Fernández, Marcial; Manzanares, Amanda||Issue Date:||12-Nov-2019||Publisher:||Public Library of Science||Citation:||PLoS ONE 14(11): e0225061 (2019)||Abstract:||[Aim] We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the hepatitis C virus (HCV) monoinfected and human immunodeficiency virus-1/hepatitis C virus (HIV/HCV) coinfected population in Spain.
[Material and methods] Data were collected from patients infected with HCV genotypes 1 or 4, with or without HIV-1 coinfection, treated with OBV/PTV/r ± DSV ± RBV at 61 Spanish sites within the initial implementation year of the first government-driven “National HCV plan.” Effectiveness was assessed by sustained virologic response at post-treatment week 12 (SVR12) and compared between monoinfected and coinfected patients using a non-inferiority margin of 5% and a 90% confidence interval (CI). Sociodemographic and clinical characteristics or patients and adverse events (AEs) were also recorded.
[Results] Overall, 2,408 patients were included in the intention-to-treat analysis: 386 (16%) were patients with HIV/HCV. Patient selection reflected the real distribution of patients treated in each participating region in Spain. From the total population, 96.6% (95% CI, 95.8–97.3%) achieved SVR12. Noninferiority of SVR12 in coinfected patients was met, with a difference between monoinfected and coinfected patients of −2.2% (90% CI, −4.5% - 0.2%). Only genotype 4 was associated with non-response to OBV/PTV/r ± DSV ± RBV treatment (p<0.001) in the multivariate analysis. Overall, 286 patients (11.9%) presented AEs potentially related to OBV/PTV/r ± DSV, whereas 347 (29.0%) presented AEs potentially related to ribavirin and 61 (5.1%) interrupted ribavirin.
[Conclusions] Our results confirm that OBV/PTV/r ± DSV ± RBV is effective and generally well tolerated in a representative sample of the HCV monoinfected and HCV/HIV coinfected population in Spain within the experience of a national strategic plan to tackle HCV.
|Publisher version (URL):||https://doi.org/10.1371/journal.pone.0225061||URI:||http://hdl.handle.net/10261/212623||DOI:||10.1371/journal.pone.0225061||E-ISSN:||1932-6203|
|Appears in Collections:||(IBIS) Artículos|
Show full item record
Files in This Item:
|journal.pone.0225061.pdf||762,66 kB||Adobe PDF|
Review this work
checked on Apr 29, 2023
checked on Jun 1, 2023
WEB OF SCIENCETM
checked on Jun 6, 2023
checked on Jun 8, 2023
checked on Jun 8, 2023
This item is licensed under a Creative Commons License